# Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07193459` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07193459](<https://clinicaltrials.gov/study/NCT07193459>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07193459

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

## Technical summary

Registry record NCT07193459. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-12 (actual); primary completion 2026-10-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT07193459, source copy `cardio:ctgov-nct07193459-2025-09-25`, retrieved 2026-10-26)
- Started: 2025-08-12 (actual) (ClinicalTrials.gov record NCT07193459, source copy `cardio:ctgov-nct07193459-2025-09-25`, retrieved 2026-10-26)
- Primary completion: 2026-10-10 (anticipated) (ClinicalTrials.gov record NCT07193459, source copy `cardio:ctgov-nct07193459-2025-09-25`, retrieved 2026-10-26)
- Completion: 2027-02-01 (anticipated) (ClinicalTrials.gov record NCT07193459, source copy `cardio:ctgov-nct07193459-2025-09-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07193459, source copy `cardio:ctgov-nct07193459-2025-09-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07193459-2025-09-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): HDM1002 200 mg
- Intervention (Drug): HDM1002 400 mg
- Intervention (Drug): Placebo
- Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (`cardio:org-hangzhou-zhongmei-huadong-pharmaceutical-co-ltd`)

## Provenance

Content hash: d452b495a2e0b1e6410f980a91ab36d0316a926fe6f789c1c0ffdbd6e34515d9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
